Home Cart Sign in  
Chemical Structure| 137628-16-1 Chemical Structure| 137628-16-1

Structure of 137628-16-1

Chemical Structure| 137628-16-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 137628-16-1 ]

CAS No. :137628-16-1
Formula : C5H3BrClNO
M.W : 208.44
SMILES Code : OC1=NC=C(Cl)C=C1Br
MDL No. :MFCD01764522
InChI Key :IPCVJZRBMDESEV-UHFFFAOYSA-N
Pubchem ID :2726791

Safety of [ 137628-16-1 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Computational Chemistry of [ 137628-16-1 ] Show Less

Physicochemical Properties

Num. heavy atoms 9
Num. arom. heavy atoms 6
Fraction Csp3 0.0
Num. rotatable bonds 0
Num. H-bond acceptors 2.0
Num. H-bond donors 1.0
Molar Refractivity 38.97
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

33.12 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.85
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.15
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.2
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.6
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.27
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.01

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.98
Solubility 0.218 mg/ml ; 0.00105 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.48
Solubility 0.694 mg/ml ; 0.00333 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.92
Solubility 0.248 mg/ml ; 0.00119 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.04 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.56

Application In Synthesis of [ 137628-16-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 137628-16-1 ]

[ 137628-16-1 ] Synthesis Path-Downstream   1~3

  • 2
  • [ 4214-79-3 ]
  • [ 137628-16-1 ]
YieldReaction ConditionsOperation in experiment
66% A mixture of 5-CHLORO-2-HYDROXYPYRIDINE (20.1 g, 155.4 MMOL) and bromine (11.9 ml) in acetic acid (250 m) was stirred at r. t. for 2 hours. Then, the solvent was evaporated in vacuo and ethyl acetate (600 ML) and saturated sodium bicarbonate (300 ML) were added. The organic layer was washed with saturated sodium bicarbonate (2X200 ML), brine and was dried (NA2SO4) and concentrated to give a solid that was crystallized from hexane/ diethyl ether. The solid 3-bromo-<strong>[4214-79-3]5-chloro-2-hydroxypyridine</strong> (21.3 g, 66percent) so obtained was used in the subsequent reaction.
With bromine; In water; acetic acid; Step 1: 3-Bromo-<strong>[4214-79-3]5-chloro-2-hydroxypyridine</strong> A mixture of <strong>[4214-79-3]5-chloro-2-hydroxypyridine</strong> (100 g) and bromine (40.1 mL) in acetic acid (400 mL) was stirred at r.t. for 1 h. The mixture was poured into 3 L of water and stirred for 30 min then filtered. The residual solid was washed with 2 L of cold water, air dried and then coevaporated with toluene three times and with benzene two times. The white solid (81 g) so obtained was used in the subsequent reaction.
With bromine; In water; acetic acid; Step 1 3-Bromo-<strong>[4214-79-3]5-chloro-2-hydroxypyridine</strong> A mixture of <strong>[4214-79-3]5-chloro-2-hydroxypyridine</strong> (100 g) and bromine (40.1 mL) in acetic acid (400 mL) was stirred at r.t. for 1 h. The mixture was poured into 3 L of water and stirred for 30 min then filtered. The residual solid was washed with 2 L of cold water, air dried and then coevaporated with toluene three times and with benzene two times. The white solid (81 g) so obtained was used in the subsequent reaction.
4.4 g With bromine; acetic acid; at 20℃; To a stirred solution of <strong>[4214-79-3]5-chloropyridin-2-ol</strong> (4 g, 31 mmol) in acetic acid (35 mL) at room temperature was added bromine (2.55 mL, 49.6 mmol) dropwise. After stirring the reaction mixture for overnight at room temperature, water was added and the mixture was extracted twice with ethyl acetate (2 x 150 mL). The organic layer was washed with water, dried over anhydrous sodium sulfate and was concentrated under reduced pressure to afford crude product. The crude product was purified by column chromatography by using silica (100-200 mesh) using 22percent EtOAc-hexane as eluent to afford the 3-bromo-<strong>[4214-79-3]5-chloropyridin-2-ol</strong> (4.4 g) as yellow solid.
With bromine; In acetic acid; at 20℃; for 48h; 5-CHLORO-2-PYRIDINOL (5.18g, 40MMOL) was dissolved in glacial acetic acid (50ml) and bromine (7. 51 G, 2. 41ml, 47mmol) added. The mixture was stirred at room temperature for 48 hours. Ethyl acetate and water were added and the organic layer washed with water (*3), dried (MGS04) and evaporated. The residue was triturated with diethyl ether and the buff solid filtered and dried (5.59g). 1H NMR (CDCI3) 7.52 (1 H, d J=3Hz), 7.87 (1 H, d J=3Hz).
With bromine; In acetic acid; at 20℃; At room temperature, bromine (1.2 mL, 24 mmol) was added dropwise to a solution of <strong>[4214-79-3]5-chloro-2-pyridinol</strong> (2.9 g, 20 mmol) in glacial acetic acid (25 mL). After stirred at room temperature overnight, ethyl acetate and water were added. The organic layer was washed with water, dried and concentrated. The residue was triturated with diethyl ether and the precipitate was filtered and dried to give the title compound (1.5 g).

  • 3
  • [ 137628-16-1 ]
  • [ 138006-41-4 ]
YieldReaction ConditionsOperation in experiment
81.76 g (89%) With trichlorophosphate; In N,N-dimethyl-formamide; EXAMPLE 3 3-Bromo-2,5-dichloropyridine To a solution of 3-bromo-5-chloropyridin-2-one (84.3 g, 0.404 mol) in DMF (100 mL) was added POCl3 (56.5 mL, 0.61 mol) via dropping funnel over 3 hours at room temperature. The resulting black solution was then heated to 70 C. and allowed to stir for 3 days. After cooling to room temperature, the solution was poured into 1 L of ice/water, filtered, and the solid dried in a vacuum oven to provide 81.76 g (89%) of the desired 3-bromo-2,5-dichloropyridine as an off-white solid, m.p. 39-41 C.: IR(CHCl3) 3867, 3663, 2989, 2734, 1812, 1606, 1547, 1400, 1366, 1230, 1155, 1129, 1074, 1027, 894, 658, 563 cm-1; 1 H NMR (300 MHz, CDCl3) delta 8.0 (d, 1H, J=2.2 Hz), 8.35 (d, 1H, J=2.2 Hz); 13 C NMR (CDCl3) delta 120.43, 130.74, 141.46, 146.64, 148.99; exact mass calculated for C5 H2 NBrCl2 =224.8748; high resolution mass spec. 224.8764.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 137628-16-1 ]

Bromides

Chemical Structure| 102830-75-1

A191983 [102830-75-1]

3-Bromo-5-chloro-2-methoxypyridine

Similarity: 0.90

Chemical Structure| 1211524-10-5

A213721 [1211524-10-5]

3-Bromo-4-chloro-2-methoxypyridine

Similarity: 0.77

Chemical Structure| 18368-59-7

A185636 [18368-59-7]

3-Bromo-4-methylpyridin-2-ol

Similarity: 0.75

Chemical Structure| 13472-59-8

A197382 [13472-59-8]

3-Bromo-2-methoxypyridine

Similarity: 0.75

Chemical Structure| 1211534-25-6

A167184 [1211534-25-6]

4-Bromo-5-chloro-2-methoxypyridine

Similarity: 0.74

Chlorides

Chemical Structure| 102830-75-1

A191983 [102830-75-1]

3-Bromo-5-chloro-2-methoxypyridine

Similarity: 0.90

Chemical Structure| 1211524-10-5

A213721 [1211524-10-5]

3-Bromo-4-chloro-2-methoxypyridine

Similarity: 0.77

Chemical Structure| 58498-61-6

A222565 [58498-61-6]

5-Chloro-3-methylpyridin-2-ol

Similarity: 0.74

Chemical Structure| 1211534-25-6

A167184 [1211534-25-6]

4-Bromo-5-chloro-2-methoxypyridine

Similarity: 0.74

Chemical Structure| 1001056-83-2

A151063 [1001056-83-2]

3-Bromo-4,5-dichloropyridine

Similarity: 0.71

Alcohols

Chemical Structure| 18368-59-7

A185636 [18368-59-7]

3-Bromo-4-methylpyridin-2-ol

Similarity: 0.75

Chemical Structure| 58498-61-6

A222565 [58498-61-6]

5-Chloro-3-methylpyridin-2-ol

Similarity: 0.74

Chemical Structure| 374633-33-7

A131401 [374633-33-7]

3-Bromo-2-hydroxy-6-picoline

Similarity: 0.73

Chemical Structure| 17282-02-9

A197426 [17282-02-9]

3-Bromo-5-methylpyridin-2-ol

Similarity: 0.73

Chemical Structure| 13472-81-6

A136524 [13472-81-6]

3,5-Dibromo-2-hydroxypyridine

Similarity: 0.73

Related Parent Nucleus of
[ 137628-16-1 ]

Pyridines

Chemical Structure| 102830-75-1

A191983 [102830-75-1]

3-Bromo-5-chloro-2-methoxypyridine

Similarity: 0.90

Chemical Structure| 1211524-10-5

A213721 [1211524-10-5]

3-Bromo-4-chloro-2-methoxypyridine

Similarity: 0.77

Chemical Structure| 18368-59-7

A185636 [18368-59-7]

3-Bromo-4-methylpyridin-2-ol

Similarity: 0.75

Chemical Structure| 13472-59-8

A197382 [13472-59-8]

3-Bromo-2-methoxypyridine

Similarity: 0.75

Chemical Structure| 58498-61-6

A222565 [58498-61-6]

5-Chloro-3-methylpyridin-2-ol

Similarity: 0.74